




RealRate

PHARMACEUTICAL 2021

Q32 Bio Inc
Rank 170 of 394

HOMOLOGY
Medicines, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Q32 Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q32 Bio Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Q32 Bio Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 33% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	219,564
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,658
Liabilities, Non-Current	45,084
Other Assets	7,171
Other Compr. Net Income	-183
Other Expenses	0
Other Liabilities	0
Other Net Income	1,569
Other Revenues	2,702
Property and Equipment	37,002
Research and Development	100,392
Selling, General and Administrative Expense	32,573

Output Variable	Value in 1000 USD
Assets	263,737
Liabilities	67,742
Expenses	132,965
Revenues	2,702
Stockholders Equity	195,995
Net Income	-128,694
Comprehensive Net Income	-128,786
BaseVar	234,449
ECR before Limited Liability	180%
Economic Capital Ratio	289%